Market Overview

The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs
Related IBB
The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug
The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US
Brinksmanship On The Hill (TalkMarkets)
5 Top-Selling Drugs With Growth Potential In 2019
Jim Cramer Gives His Opinion On Ciena, Momo, Qualcomm And More
Despite The Market Rally These Dividend Stocks Are Strong Buys (Seeking Alpha)

The ASCO conference closed Tuesday, although presentations at the conference triggered some huge stocks moves. Nektar Therapeutics (NASDAQ: NKTR) slumped about 42 percent, while Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) has rallied about 60 percent since June 1.

Here's a look at the upcoming week's catalytic events.


  • 41st European Congress of Cytology – June 10-13, in Madrid, Spain
  • 31st International Conference On Antiviral Research, or ICAR - June 11-15, in Porto, Portugal
  • Goldman Sachs 39th Annual Global Healthcare Conference – June 12-14, in Rancho Palos Verdes, California
  • Annual European Congress of Rheumatology, 2018 – June 13-16, in Amsterdam, Netherlands
  • UK Oncology Forum – June 14-15, in Liverpool, U.K.
  • 23rd Congress of European Hematology Association, or EHA, – June 14-17, in Stockholm, Sweden
  • 52nd European Human Genetics Conference in conjunction with the European Meeting on Psychological Aspects of Genetics – June 16-19, in Milan, Italy

Related Link: Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates

Clinical Trial Presentations

Chimerix Inc (NASDAQ: CMRX) is due to present Phase 1 data on its norovirus treatment candidate CMX521 at the ICAR between June 11-15. The company recently received orphan drug designation to its smallpox treatment candidate brincidofovir.

Beigene Ltd (ADR) (NASDAQ: BGNE) will present Phase 1/2 data for its Zanubrutinib, its treatment candidate for Waldenstrom's macroglobulinemia, at the EHA on Friday.

AbbVie Inc (NYSE: ABBV) and Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) will present Phase 3 data for Venclexta, their relapsed or refractory chronic lymphocytic leukemia, or CLL, treatment candidate, at the EHA on Saturday.

bluebird bio Inc (NASDAQ: BLUE) is due to present Phase 3 data on LentiGlobin, code named HGB-207, from a study called Northstar-2, which evaluated the pipeline candidate for non-beta0/beta0 transfusion-dependent thalassemia, at the EHA on Saturday.


Verrica Pharmaceuticals, a clinical-stage dermatology company, is scheduled to IPO, offering 5 million shares at an estimated price range of $14 to $16. The company seeks to list its shares on the Nasdaq under the ticker symbol VRCA.

Posted-In: Biotech News Previews IPOs Top Stories Trading Ideas Best of Benzinga


Related Articles (ABBV + BGNE)

View Comments and Join the Discussion!

The IPO Outlook For The Week Of June 11: Pharma, Software And Logistic Firms

A Look At Investor Psychology Ahead Of Important Events